Signal Genetics Inc. (Nasdaq: SGNL) will hold a special shareholder meeting on February 10, 2017 to vote on matters related to the company's proposed merger with Miragen Therapeutics and the sale of Signal's MyPRS intellectual property assets. Shares of the molecular genetic diagnostic company rocketed $12.69 to close at $17.48.